Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Zamtocabtagene autoleucel: mechanism of production & potential implications for access

Matthew Ulrickson • 15 Jun 2023
ICML 2023
General CAR-T Zamtocabtagene autoleucel

Matthew Ulrickson, MD, Banner MD Anderson Cancer Center, Gilbert, AZ, comments on the mechanism of production for zamtocabtagene autoleucel (zamto-cel) and explains how this may potentially improve access to this agent. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Matthew Ulrickson

1:09
The changing role of alloSCT in DLBCL in the era of novel agents
Matthew Ulrickson • 15 Jun 2023
1:09
Optimizing CAR-T outcomes in DLBCL: possible combination strategies & sequencing of agents
Matthew Ulrickson • 15 Jun 2023
1:33
Zamtocabtagene autoleucel for the treatment of patients with R/R DLBCL
Matthew Ulrickson • 15 Jun 2023

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals